Thelansis

  Alveolar soft part sarcoma (ASPS) is a malignant soft tissue tumor, which is a tumor that begins in the body's soft connective tissues, such as fat, muscles, or nerves. ASPS is one of the most uncommon sarcomas. Soft tissue sarcomas account for 1% of all cancers, and ASPS accounts for 0.2% to 1% of all soft tissue sarcomas. In the United States, approximately 80 cases are diagnosed each year. Thelansis’s “Alveolar Soft Part Sarcoma (ASPS) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alveolar Soft Part Sarcoma (ASPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Alveolar Soft Part S...